18,770 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Verus Capital Partners LLC

Verus Capital Partners LLC acquired a new stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) during the third quarter, Holdings Channel reports. The fund acquired 18,770 shares of the company’s stock, valued at approximately $699,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SRRK. Vanguard Group Inc. raised its position in shares of Scholar Rock by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock valued at $183,032,000 after buying an additional 53,333 shares during the last quarter. Bellevue Group AG increased its holdings in shares of Scholar Rock by 17.6% in the second quarter. Bellevue Group AG now owns 2,947,295 shares of the company’s stock valued at $104,393,000 after purchasing an additional 440,405 shares during the last quarter. Eventide Asset Management LLC lifted its position in Scholar Rock by 9.5% during the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock worth $103,192,000 after buying an additional 251,638 shares in the last quarter. Hood River Capital Management LLC lifted its position in Scholar Rock by 1.6% during the second quarter. Hood River Capital Management LLC now owns 1,974,964 shares of the company’s stock worth $69,953,000 after buying an additional 30,806 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Scholar Rock by 2.2% during the second quarter. Geode Capital Management LLC now owns 1,887,410 shares of the company’s stock worth $66,861,000 after buying an additional 39,961 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Analysts Set New Price Targets

SRRK has been the subject of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Citigroup started coverage on shares of Scholar Rock in a report on Friday, January 9th. They issued a “buy” rating and a $55.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Finally, UBS Group started coverage on Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock. Four research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Scholar Rock currently has a consensus rating of “Buy” and a consensus target price of $51.14.

Insider Transactions at Scholar Rock

In related news, insider Jing L. Marantz sold 4,157 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $193,425.21. Following the transaction, the insider owned 126,012 shares of the company’s stock, valued at approximately $5,863,338.36. This represents a 3.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Junlin Ho sold 9,580 shares of Scholar Rock stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $445,757.40. Following the completion of the transaction, the general counsel directly owned 241,545 shares of the company’s stock, valued at approximately $11,239,088.85. This represents a 3.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 336,448 shares of company stock valued at $14,971,883. Corporate insiders own 13.30% of the company’s stock.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $47.01 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a market cap of $4.80 billion, a P/E ratio of -14.92 and a beta of 0.67. The firm’s 50 day moving average price is $45.20 and its 200-day moving average price is $38.52. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $49.82.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).